Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...
A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback